©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Role of β2-microglobulin in uremic patients may be greater than originally suspected
Aysegul Zumrutdal, Nephrology Department, Baskent University Adana Teaching and Research Center, Baskent University Hospital, Yuregir, Adana 01230, Turkey
Author contributions: Zumrutdal A solely contributed to this work.
Correspondence to: Aysegul Zumrutdal, MD, Professor, Nephrology Department, Baskent University Adana Teaching and Research Center, Baskent University Hospital, Yuregir, Dadaloglu Mah, 2591 St, 4/A, Adana 01230, Turkey. azumrutdal@yahoo.com
Telephone: +90-322-3272727 Fax: +90-322-3271274
Received: June 17, 2014
Peer-review started: June 18, 2014
First decision: August 14, 2014
Revised: September 3, 2014
Accepted: October 1, 2014
Article in press: October 10, 2014
Published online: February 6, 2015
Processing time: 234 Days and 17.8 Hours
Peer-review started: June 18, 2014
First decision: August 14, 2014
Revised: September 3, 2014
Accepted: October 1, 2014
Article in press: October 10, 2014
Published online: February 6, 2015
Processing time: 234 Days and 17.8 Hours
Core Tip
Core tip: Previously, the clinical significance of beta2-microglobulin (β2M) in uremic patients was limited to β2M-derived amyloidosis; in recent years, its role and power has changed and expanded. Although there have been some inconsistencies among the various analyses relating to β2M, the data generally support β2M as a promising novel marker of kidney function by predicting cardiovascular (CV) risk, CV events and overall mortality.